Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Erythropietin on Microcircualtory Alteration in Intensive Care Unit Patients With Severe Sepsis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patients must be 18 years old and over to be included in the study. They must meet criteria for sepsis defined as:40~  1. Two or more criteria for the systemic inflammatory response syndrome (SIRS):~     * heart rate greater than 90 beats per minute, or paced, or taking beta-blockers or the calcium channel blockers verapamil or diltiazem~    * respiratory rate greater than 20 breathes per minute, or a PaC02 less than 32 mmHg, or mechanically ventilated~    * temperature greater than 38 or less than 36 degrees Celsius~    * white blood cell count greater than 12 x 109/L or less than 4 x 109/L, or more than 10% bands on the differential.~ 2. Suspected or confirmed source of infection~     And either one of the following definitions:~ 3. Severe Sepsis: Sepsis with at least one organ dysfunction defined as urine output \< 0.5 ml/kg/hr for 1 hour, PaO2/FiO2 \< 250 (less than 200 if lung is the only dysfunctional organ), platelets \< 80 x109/L or a 50% decrease from baseline in the past 3 days, or pH \< 7.30 or lactate \> 1.5 mmole/L upper normal with base deficit \> 5~ 4. Septic shock \<48hrs: Persistent arterial hypotension with a systolic pressure \< 90 mmHg or a MAP \< 60 mmHg or a reduction of in systolic blood pressure \> 40 mmHg from baseline, despite adequate fluid resuscitation in the absence of other cause for hypotension or requiring the administration of a pressor agent to maintain the above blood pressure.~Exclusion Criteria:~* Clinically apparent other forms of shock including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax) or hemorrhagic shock~* A known previous severe reaction to erythropoietin~* Uncontrolled hypertension (hypertensive urgency, hypertensive emergency and hypertensive encephalopathy)~* Myocardial infarction and/or stroke within one month~* Hypersensitivity reaction after previous rh-EPO use. Known sensitivity to products from mammalian cell cultures~* Previous history of deep venous thromboses or pulmonary embolism~* Burns~* Cirrhosis~* Traumatic brain injury~* Less than 18 years of age~* Family or patient not committed to aggressive care~* Currently enrolled in another related interventional study~* Any active cancer patients of any type and stage except for patients with basal and squamous cell skin cancers~* Patient weighing \> 100 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage1 (Type: None): 1. Prospective dose response group. 3 subjects per dose at 200U/kg, 400U/kg and 600U/kg rHuEPO
- Stage 2 Randomized, blinded trial (Type: None): Control group: Randomized to placebo treatment Treatment Group: Randomized to rHuEPO treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).